Floatz logo

Selinexor

Recurrent and Refractory Diffuse Large B-cell Lymphoma

Chengdu Zenitar Biomedical Technology Co., LtdSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

107 Active assets in the Recurrent and Refractory Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Axicabtagene Ciloleucel
Zhujiang Hospital
Phase 3BB
Cyclophosphamide
Nathan Denlinger
Phase 3BB
ETOPOSIDE
University of California, Davis
Phase 3BB
Ifosfamide
University of California, Davis
Phase 3BB

View all 50 →

Same molecule, other indications

Selinexor is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →